Cellulaze Cellulite Laser Treatment at Manhattan Surgical Care, New York CityManhattan Surgical Care in NYC is at the forefront of cellulite treatment with Cellulaze, the only FDA minimal invasive cellulite treatment with long lasting results
By: Manhattan Surgical Cellulite reduction treatment with Cellulaze by Cynosure is safe and effective. Cellulaze is the only FDA approved long term cellulite treatment which is minimally invasive. Cellulaze is the world's first one-time treatment for cellulite. Basil Pakeman MD at Manhattan Surgical Care is one of the few body sculpting surgeon selected by cynosure to provided cellulaze in New York, NY. (http://www.nycsurgical.com/ Cynosure's Cellulaze Cellulite treatment directly addresses the underlining structure of cellulite, providing clinically proven results in a single Treatment. Cellulaze™ reduces the hills and valleys commonly found on the surface of thighs, hips, back of legs, abdomen, and buttocks. Cellulite does not respond to exercise or dieting, and the causes are multifactorial including weight loss, weight gain, hormonal, pregnancy, puberty, and aging. Cellulaze is an innovative technology that uses pulsed Nd:YAG 1440 nm wavelength with a bidirectional SideLight fiber. Cellulite laser treatment by Cellulaze effectively targets the structure of cellulite by: ◦Thermally subcision and release of the fibrous septae ◦Target pockets of bulging fat ◦Thicken and tighten the dermis Cellulaze treatment is offered only by qualified surgeons who have successfully completed an accredited training through Cynosure. Smartlipo body sculpting laser is amount the many innovative technologies that Cynosure had developed along with Cellulaze Laser . For more information regarding Cellulaze cellulite treatment, and to schedule your consultation, please contact Manhatan Surgical Care in NYC at 212 308-1566 or http://www.nycsurgical.com/ Photos: https://www.prlog.org/ https://www.prlog.org/ End
Account Email Address Account Phone Number Disclaimer Report Abuse Page Updated Last on: May 04, 2012
|